Stock Events

Stock Events

E-Therapeutics 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Schwab U.S. Broad Market
SCHB
Mkt Cap0
Schrodinger operates in computational drug discovery, directly competing with E-Therapeutics' network-driven drug discovery approach.
Illumina
ILMN
Mkt Cap35.63B
Illumina provides sequencing and array-based solutions for genetic analysis, which is foundational to the kind of computational biology E-Therapeutics engages in.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is focused on gene editing, a cutting-edge area of biotech that competes for similar research attention and funding as E-Therapeutics' drug discovery platform.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine works on gene editing, directly competing in the innovative biotech space where E-Therapeutics operates, especially in novel drug discovery.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is another gene editing company, competing in the biotech innovation space, relevant to E-Therapeutics' focus on novel therapeutic discovery.
Beam Therapeutics
BEAM
Mkt Cap2.81B
Beam Therapeutics specializes in precision genetic medicines, competing in the cutting-edge area of biotech that overlaps with E-Therapeutics' innovative drug discovery methods.
Twist Bioscience
TWST
Mkt Cap10.13B
Twist Bioscience operates in synthetic biology, producing synthetic DNA that is foundational for biotech research, competing with E-Therapeutics in the broader biotech innovation space.
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences offers sequencing systems, essential for the genetic analysis that underpins the computational drug discovery efforts of companies like E-Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals is a biotech company that, while larger and more established, competes for market share in the innovative drug discovery and development space, relevant to E-Therapeutics' operations.

About

e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
Show More
CEO
Mr. Ahmad Ali Mortazavi
Employees
34
Country
United Kingdom
ISIN
GB00B2823H99
WKN
000A0M8VQ

Listings

STU
DE
3AQ.STU

0 Comments

Share your thoughts

FAQs

What is E-Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange E-Therapeutics stocks are traded under the ticker 3AQ.STU.
How many employees does E-Therapeutics have?▼
As of November 2, 2026, the company has 34 employees.
In which sector is E-Therapeutics located?▼
E-Therapeutics operates in the Health & Wellness sector.
When did E-Therapeutics complete a stock split?▼
E-Therapeutics has not had any recent stock splits.
Where is E-Therapeutics headquartered?▼
E-Therapeutics is headquartered in London, United Kingdom.